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mg/m2 (IRMA 1, 2, 3, 5) or Cetuximab 400 mg/m2 (IRMA 4). A 
dose of 67.5 Gy in 30 fractions (IRMA 1, 2, and 4) or 70.5 Gy 
in 30 fractions (IRMA 3, 4, and 5) was delivered to primary 
tumor and involved nodes, 60 Gy were delivered to high risk 
and 55.5 Gy to low risk lymph node areas. Static (IMRT) or 
volumetric (VMAT) intensity modulated technique with 
simultaneous integrated boost was used. 
 
Results: 107 patients (median age 56 years, range 30-78, 
UICC stage III: n = 18, IV: n = 89) were included in this 
analysis. IC was performed with Cisplatin + 5-Fluorouracil in 
65 (61%) patients and with Docetaxel + Cisplatin + 5-
Fluorouracil in 42 (39%) cases. Concomitant Cisplatin and 
Cetuximab were administered in 84% and in 16% of patients, 
respectively. 51% (n = 55) of cases were irradiated with step 
& shoot IMRT-SIB technique (7 beams), while 49% (n = 52) of 
patients were irradiated with VMAT-SIB (two arcs) technique. 
During radio-chemotherapy, 23 (21%) patients developed 
mucositis, 12 (11%) G3 dysphagia and 10 (9.3%) G3 
hematological toxicity. Even 1 (0.9%) G4 leukopenia and 3 
(2.8%) G5 (2 neutropenia and one fatal myocardial infarction) 
adverse events were observed. The overall response rate 
after radio-chemotherapy was 82.2%. Two-year local control 
and survival were 64.2% and 64.6% (IRMA 1), respectively, 
57.8% and 56.2% (IRMA 2), 66.4% and 75.5% (IRMA 3), 70.1% 
and 66.7% (IRMA 4), and 76.5% and 82.4% (IRMA 5), 
respectively. 
 
 
 
Conclusion: In our experience moderately hypofractionated 
and accelerated radio-chemotherapy after induction 
chemotherapy was feasible. Intensive patient monitoring and 
supportive strategies during chemoradiation are necessary to 
manage of side effects. 
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Purpose or Objective: To analyse the frequency and severity 
of dysphagia and xerostomia in patients affected by 
nasopharyngeal and oropharyngeal cancers treated by 
intensity-modulated radiotherapy (IMRT) and the correlation 
with volumetric variations and dosimetric data of pharyngeal 
constrictor muscles and parotid glands.  
 
Material and Methods: Fifty patients, who underwent 
adaptive IMRT for nasopharyngeal and oropharyngeal cancers, 
were included in the present study. Eighty-four percent of 
patients (42/50) received concurrent radio-chemotherapy 
and 92% (44/50) were in locally advanced stage. Dose-volume 
parameters related to constrictor muscles (superior 
constrictor muscle, SCM; middle constrictor muscle, MCM; 
inferior constrictor muscle, ICM and whole pharyngeal 
constrictor muscle, CM), and parotid glands were analyzed 
using dose-volume histograms (DVHs). All patients underwent 
replanning CT scan after 5 weeks of radiation therapy and 
the target and OARs were re-contoured on fusion images 
after co-registration. The volumetric variations of pharyngeal 
constrictor muscles and parotid glands were measured. 
Volumetric variations and dose-volume parameters were 
associated to acute and late dysphagia and xerostomia 
according to RTOG score, quality of life questionnaires (PSS-
H&N e QLQ-H&N35), and oesophageal transit . 
 
Results: Volumetric variations and dose-volume parameters 
of pharyngeal constrictor muscles and parotid glands are 
reported in Table 1. Adaptive IMRT achieved a good sparing 
of parotid glands (mean dose 24.9 Gy) and constrictor 
muscles (mean dose 51.2 Gy). Acute dysphagia, was scored as 
grade 0-1 in 18/50 patients (36%) and as grade 2-3 in 32/50 
(64%). Acute xerostomia, was scored as grade 0-1 in 21/50 
patients (42%) and as grade 2-3 in 29/50 (58%). Volumetric 
variations and dose-volume parameters of the constrictor 
muscles and parotid glands did not correlate with acute 
toxicity (p>0.05). At 2 years median follow-up (range 6-67 
months), late dysphagia was scored as grade 0-1 in 40/50 of 
patients (80%) and as grade 2-3 in 10/50 (20%). Late 
xerostomia was scored as grade 0-1 in 42/50 of patients (84%) 
and as grade 2-3 in 8/50 (16%). The analysis of the 
correlation of volumetric variations and dose-volume 
parameters with clinical data (RTOG score for late toxicity, 
quality of life questionnaires and oesophageal transit) is 
ongoing. 
 
 
 
Conclusion: During radiotherapy, pharyngeal constrictor 
muscles and salivary glands underwent volumetric variations. 
Volumetric variations and dosimetric findings did not 
correlate with acute toxicity, probably because of the 
complexity and multifactorial pathogenesis of acute 
dysphagia and xerostomia. The ongoing analysis on the 
correlation of late toxicity data with volumetric variations 
and dose-volume parameters may help in the optimization of 
IMRT treatment planning. 
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Purpose or Objective: At our center, the need for neck 
dissection (ND) after radiotherapy (RT) is determined based 
on the nodal response on the post-RT Computed Tomography 
(CT) study 4 months after the end of treatment. We want to 
report the outcome of this approach and investigate whether 
characteristics on pre- and post- RT CT studies can predict 
the necessity of post-RT ND. 
 
Material and Methods: Between 2002 and 2012, 183 
consecutive patients with lymph node-positive head and neck 
cancer (HNC) were treated with RT or concurrent 
chemoradiotherapy (CRT) without planned ND. CT studies 
pre- and post-treatment were reviewed for lymph node size 
and presence of necrosis, extracapsular spread and 
calcifications. At patient level, data were correlated with 3 
year regional control (RC), metastasis free survival (MFS), 
disease free survival (DFS) and overall survival (OS). At nodal 
level, data were correlated with relapse of the individual 
lymph nodes (LNR). A stepwise selection procedure was 
followed to construct a multivariable prediction model for 
regional relapse (RR) within 3 years. The area under the ROC 
curve (AUC) was determined for the selected model. 
Additionally a bootstrap-corrected AUC value was calculated. 
This AUC value corrects for overoptimism resulting from the 
fact that model construction and model validation were 
performed on the same data set. 
 
Results: The median follow-up was 60 months. 3-year 
outcome rates were as follows: LC of 84%, RC of 80%, MFS of 
74%, DFS of 61%, OS of 63%. Pre-treatment nodal size at 
patient- and nodal level and presence of necrosis at patient 
level were associated with a poorer outcome. This was also 
the case for post-treatment lymph node size and presence of 
necrosis and extracapsular spread (Table 1). Based on our 
results we developed a multivariate model for RR prediction. 
After performing a stepwise selection procedure pre-RT T 
stage (p=0.02), post-RT necrosis (p=0.03) and post-RT largest 
nodal diameter (p=0.01) were included in the model. The 
AUC of this model was 0.78 (95% CI 0.63;0.84); the bootstrap-
corrected AUC was 0.74 (95% CI 0.67; 0.89). The risk for RR 
within 3 years can be calculated using the following formula:  
 
 
 
Conclusion: Characteristics on the post-RT CT study can 
predict the likelihood of residual lymph node disease and 
outcome. Characteristics on the pre-therapy CT study seem 
less useful for this purpose. A CT-based multivariate 
prognostic model based on our findings was developed which 
can aid in predicting RR. 
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Purpose or Objective: With the success of Intensity 
Modulated Radiotherapy (IMRT) techniques in reducing the 
severity of xerostomia in head and neck cancer (HNC) 
patients, efforts should be made to improve swallowing 
dysfunction, which is potentially even more discomforting 
and incapacitating side effect and adversely affects the 
quality of life. This is a clinical dosimetric study to 
investigate the correlation between radiation doses delivered 
to organs at risk for radiation induced swallowing dysfunction 
(SWOARs) and severity of dysphagia following concurrent 
chemoradiotherapy to HNC patients and evaluate various 
factors which assume importance in determining the risk of 
dysphagia/aspiration.  
 
Material and Methods: 60 Head and Neck cancer patients 
(Oropharynx 28, Hypopharynx 12 and Larynx 20) were 
enrolled between May 2013 and June 2014 for this 
prospective longitudinal study after prior approval from the 
hospital ethics and review committee. Patients were treated 
with curative intent by radiotherapy using IMRT and 
concurrent chemotherapy using cisplatin (40 mg/m2) on 
weekly basis. Delineation of SWOARs was done using RTOG 
guidelines and following structures were contoured: superior, 
middle and inferior pharyngeal constrictor, cricopharyngeal 
muscle, esophageal inlet muscle, cervical esophagus, base of 
tongue, supraglottic and glottic larynx. Dysphagia endpoints 
included both patient-reported (EORTC Head and Neck 
Quality of Life instrument and MD Anderson Dysphagia 
Inventory) and observer-rated scores (Common Terminology 
Criteria for Adverse Events- CTCAE v4.0 and RTOG/EORTC 
Late Radiation Morbidity Scoring). Patients were assessed 
weekly during radiation and at 1 month and 3 months after 
completion of treatment. Correlation between dysphagia and 
radiation doses to SWOARs was assessed.  
 
Results: With an increase in the mean dose to the SWOARs, 
the grades of dysphagia also increased. After 3 months of 
completion of treatment, 27% patients had persistent 
dysphagia of grade 3 or grade 4. Significant correlation was 
observed between patient reported dysphagia scores and the 
mean doses to the superior and middle pharyngeal constrictor 
as well as glottic and supraglottic larynx (p<0.05). Observer 
rated dysphagia scores correlated significantly with mean 
superior pharyngeal constrictor dose and not with dose to 
other SWOARs. Two patients of carcinoma hypopharynx 
developed stricture which correlated significantly with dose 
to esophageal inlet muscle.  
 
Conclusion: Radiotherapy plans sparing SWOARs should be 
generated and implemented to prevent the problem of 
dysphagia. The structures whose damage may cause 
dysphagia and aspiration are the pharyngeal constrictors and 
the glottic and supraglottic larynx. Further studies are 
required to evaluate dose constraints to these SWOARs to 
reduce the incidence of radiation induced dysphagia and thus 
further improve the quality of life in HNC patients. 
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